Despite widespread hype, artificial intelligence faces significant regulatory and practical barriers that prevent it from automatically speeding up clinical trial timelines.

AI tools require substantial validation and regulatory approval before they can be integrated into clinical trial workflows, adding rather than eliminating delays.

Data quality and standardization issues in healthcare settings limit AI's ability to meaningfully accelerate patient recruitment and trial design processes.

Clinical trials remain constrained by biological factors and regulatory requirements that AI cannot bypass, regardless of technological capabilities.

Organizations must invest heavily in infrastructure, training, and compliance to realize any potential AI benefits in trial acceleration.